前瞻性比较[68Ga]Ga-FAPI-04 PET/MRI、[18F]FDG PET/CT与增强MRI预测乳腺癌新辅助化疗后病理完全缓解
结果显示原发灶pCR率为60.00%、腋窝淋巴结pCR率为72.73%;治疗后[68Ga]Ga-FAPI-04 SUVmax预测原发灶反应的AUC为0.84,SULmean预测淋巴结反应的AUC为0.89,后者在DeLong检验中优于最佳[18F]FDG参数。
要点
- 治疗后[68Ga]Ga-FAPI-04 SUVmax预测原发灶pCR的AUC为0.84,敏感度、特异度和准确率均为80.00%。
- 治疗后[68Ga]Ga-FAPI-04 SULmean预测腋窝淋巴结pCR的AUC为0.89,敏感度91.67%、特异度81.25%、准确率84.09%。
- MRI预测原发灶和淋巴结反应的AUC分别为0.733和0.770,间质FAP表达与[68Ga]Ga-FAPI-04 SUVmax正相关。
核心结论
- 治疗后[68Ga]Ga-FAPI-04 PET可能为乳腺癌新辅助化疗后反应评估提供有用的辅助信息,尤其在腋窝淋巴结评估方面。
主要发现
- 共获得25个原发病灶、44个转移性淋巴结(分布于27个腋窝分区);原发灶pCR率为60.00%,腋窝淋巴结pCR率为72.73%。
- 预测原发灶反应时,治疗后[68Ga]Ga-FAPI-04 SUVmax的AUC为0.84,最佳[18F]FDG参数为ΔTBR%(AUC 0.747)。
- 预测淋巴结反应时,治疗后[68Ga]Ga-FAPI-04 SULmean的AUC为0.89,且在DeLong检验中优于最佳[18F]FDG参数。
- MRI预测原发灶和淋巴结反应的AUC分别为0.733和0.770;间质FAP表达与[68Ga]Ga-FAPI-04 SUVmax呈正相关。
关键数值与推荐
- 原发灶反应:治疗后[68Ga]Ga-FAPI-04 SUVmax的AUC为0.84,敏感度、特异度和准确率均为80.00%。
- 淋巴结反应:治疗后[68Ga]Ga-FAPI-04 SULmean的AUC为0.89,敏感度91.67%、特异度81.25%、准确率84.09%。
- 最佳[18F]FDG原发灶参数为ΔTBR%,AUC为0.747;MRI原发灶与淋巴结AUC分别为0.733和0.770。
临床怎么用
- 治疗后[68Ga]Ga-FAPI-04 PET可作为乳腺癌新辅助化疗后反应评估的辅助手段,尤其用于腋窝淋巴结评估,可能支持更个体化的术前规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate assessment of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) remains challenging in breast cancer. This prospective single-center study compared [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic response after NAC. METHODS: Women with biopsy-confirmed stage II-III breast cancer underwent baseline and post-therapy [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI before surgery. PET parameters were analyzed for primary tumors and axillary nodes. Selected variables were evaluated using LASSO and receiver-operating-characteristic analyses. Stromal FAP expression was assessed immunohistochemically in paired specimens. RESULTS: Twenty-four patients completed the protocol, yielding 25 primary lesions and 44 metastatic lymph nodes across 27 axillary compartments. The pCR rate was 60.00% for primary lesions and 72.73% for axillary nodes. For primary-lesion response, post-therapy [68Ga]Ga-FAPI-04 SUVmax showed the highest performance (AUC, 0.84; sensitivity, specificity, and accuracy, 80.00% each); the best [18F]FDG parameter was ΔTBR% (AUC, 0.747). For nodal response, post-therapy [68Ga]Ga-FAPI-04 SULmean showed the highest performance (AUC, 0.89; sensitivity, 91.67%; specificity, 81.25%; accuracy, 84.09%) and exceeded the best [18F]FDG parameter on DeLong testing. MRI AUCs were 0.733 and 0.770 for primary and nodal disease, respectively. Stromal FAP expression correlated positively with [68Ga]Ga-FAPI-04 SUVmax. CONCLUSION: Post-therapy [68Ga]Ga-FAPI-04 PET may provide useful adjunctive information for response assessment after NAC in breast cancer, particularly for axillary nodal evaluation, potentially supporting more individualized preoperative planning. TRIAL REGISTRATION: ClinicalTrials.gov, NCT07553741, retrospectively registered.
引用
- Luo Y, Zhang X, Li R, et al. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42489707. doi:10.1007/s00259-026-08091-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。